title: Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension.
abstract: To assess the short-term metabolic effects a long-acting non-sulphydryl ACE-inhibitor benazepril on glycaemic control in Type 2 diabetes mellitus and arterial hypertension, 10 hypertensive diabetic patients treated with glibenclamide were studied in a double-blind, crossover fashion over two 10-day periods in which either benazepril (10 mg/day) or placebo was given. At the end of the 10 day treatment, both blood pressure and plasma glucose concentrations were lower after benazepril versus placebo (benazepril, blood pressure: 143 +/- 11/83 +/- 5 mmHg, plasma glucose: 7.1 +/- 1.2 mmol/l; placebo: blood pressure: 157 +/- 10/99 +/- 2 mmHg, plasma glucose: 8.2 +/- 1 mmol/l, p < 0.05). In response to an oral glucose tolerance test combined with 1 mg intravenous glibenclamide, plasma glucose levels were lower after benazepril versus placebo (0-460 min: 8.4 +/- 0.8 versus 10.5 +/- 0.9 mmol/l, p < 0.05), whereas plasma insulin, C-peptide and glibenclamide concentrations were not different. It is concluded that a short-term administration of benazepril in Type 2 diabetes mellitus reduces blood pressure and improves blood glucose control, most likely by decreasing insulin resistance.
authors.affiliation: Istituto di Medicina Interna e Scienze Endocrine e Metaboliche, Università di Perugia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: De Feo
authors.forename: E
authors.initials: E
authors.lastname: Torlone
authors.forename: G
authors.initials: G
authors.lastname: Perriello
authors.forename: C
authors.initials: C
authors.lastname: Fanelli
authors.forename: L
authors.initials: L
authors.lastname: Epifano
authors.forename: A
authors.initials: A
authors.lastname: Di Vincenzo
authors.forename: F
authors.initials: F
authors.lastname: Modarelli
authors.forename: M
authors.initials: M
authors.lastname: Motolese
authors.forename: P
authors.initials: P
authors.lastname: Brunetti
authors.forename: G B
authors.initials: GB
authors.lastname: Bolli
mesh_terms: D000284:Administration, Oral; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D005951:Glucose Tolerance Test; D005905:Glyburide; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001552:Benzazepines; D001786:Blood Glucose; D005905:Glyburide; C044946:benazepril